Phase II Trial of Neoadjuvant Dose-Dense Doxorubicin, Ifosfamide, and Irinotecan (CPT-11) for Advanced Soft Tissue and Recurrent Bone Sarcomas.

Trial Profile

Phase II Trial of Neoadjuvant Dose-Dense Doxorubicin, Ifosfamide, and Irinotecan (CPT-11) for Advanced Soft Tissue and Recurrent Bone Sarcomas.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Dexrazoxane (Primary) ; Doxorubicin; Ifosfamide; Irinotecan
  • Indications Ewing's sarcoma; Neuroectodermal tumours; Osteosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2011 Planned end date (1 Oct 2012) added as reported by ClinicalTrials.gov.
    • 13 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top